Short stature and primary ovarian insufficiency possibly due to chromosomal position effect in a balanced X;1 translocation. by Genesio, R. et al.
CASE REPORT Open Access
Short stature and primary ovarian
insufficiency possibly due to chromosomal
position effect in a balanced X;1
translocation
Rita Genesio1†, Angela Mormile1†, Maria Rosaria Licenziati2, Daniele De Brasi3, Graziella Leone1, Sara Balzano4,
Antonella Izzo1, Ferdinando Bonfiglio1, Anna Conti1*, Gennaro Fioretti5, Selvaggia Lenta2, Maria Rita Poggiano2,
Paolo Siani3 and Lucio Nitsch1
Abstract
Background: Primary ovarian insufficiency (POI) is defined as a primary ovarian defect characterized by absent
menarche (primary amenorrhea), a decrease in the initial primordial follicle number, high follicle-stimulating
hormone (FSH) levels and hypoestrogenism. Although the etiology of a majority of POI cases is not yet identified,
several data suggest that POI has a strong genetic component. Conventional cytogenetic and molecular analyses
have identified regions of the X chromosome that are associated with ovarian function, as well as POI candidate
genes, such as FMR1 and DIAPH2.
Here we describe a 10.5-year-old girl presenting with high FSH and luteinizing hormone (LH) levels, pathologic GH
stimulation arginine and clonidine tests, short stature, pterygium, ovarian dysgenesis, hirsutism and POI.
Results: Cytogenetic analysis demonstrated a balanced reciprocal translocation between the q arms of
chromosomes X and 1, with breakpoints falling in Xq21 and 1q41 bands. Molecular studies did not unravel any
chromosome microdeletion/microduplication, and no XIST-mediated inactivation was found on the derivative
chromosome 1. Interestingly, through immunofluorescence assays, we found that part of the Xq21q22 trait,
translocated to chromosome 1q41, was late replicating and therefore possibly inactivated in 30 % metaphases both
in lymphocytes and skin fibroblasts, in addition to a skewed 100 % inactivation of the normal X chromosome.
These findings suggest that a dysregulation of gene expression might occur in this region. Two genes mapping to
the Xq translocated region, namely DIAPH2 and FMR1, were found overexpressed if compared with controls.
Conclusions: We report a case in which gonadal dysgenesis and POI are associated with over-expression of
DIAPH2 gene and of FMR1 gene in wild type form. We hypothesize that this over-expression is possibly due to a
phenomenon known as “chromosomal position effect”, which accounts for gene expression variations depending
on their localization within the nucleus. For the same effect a double mosaic inactivation of genes mapping to the
Xq21-q22 region, demonstrated by immunofluorescence assays, may be the cause of a functional Xq partial
monosomy leading to most Turner traits of the proband’s phenotype.
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Background
Primary ovarian insufficiency (POI) is a condition caused
by the absence, non functionality or early depletion of
the ovarian reserve. The term is now commonly used to
indicate conditions as hypergonadotropic hypogonadism,
premature ovarian failure (POF) and ovarian dysgenesis
[1]. POI may include either severe forms, presenting
with absent pubertal development and primary amenor-
rhea, or milder forms with post-pubertal onset charac-
terized by disappearance of menstrual cycles (secondary
amenorrhea) and defective folliculogenesis. POI is gener-
ally characterized by low levels of gonadal hormones (es-
trogens and inhibins) and high levels of gonadotropins
(LH and FSH) (hypergonadotropic amenorrhea) [2].
Another indicator is the anti-Mullerian hormone (AMH),
which can help to assess the state of follicular senescence.
It is considered a possible predictor of the ovarian reserve
even before menarche. [3].
Several data indicate that POI has a strong genetic
component. It is often associated with X chromosomal
abnormalities [4], including X monosomy (Turner syn-
drome) or trisomy even in mosaic form, X chromosome
deletions, inversions and balanced and unbalanced
X;autosomal (X;A) translocations [5–7].
Cytogenetic and molecular analysis of POI women car-
rying X-rearrangements allowed the identification of a
“critical region” for ovarian development and function
on the long arm of the X chromosome, ranging from
Xq13.3 to q27. It could be divided into two distinct por-
tions, namely the critical region 1, which mainly overlaps
the Xq21 band and the critical region 2, which spans
from Xq23 to Xq27 [8, 9, 4]. POI was often associated
either to interstitial deletions within Xq23–q27 or to
balanced X;A translocations with breakpoints mapping
to the Xq13–q21 region. However, most of breakpoints
described in POI patients mapped to intragenic regions,
consistently with models involving chromosome dy-
namic effects [10, 11], such as the “chromosomal pos-
ition effect” (CPE) [12], possibly associated with X;A
translocations [13]. Few characterizations of breakpoint
regions in X;A balanced translocations presenting with
POI led to the identification of interrupted genes map-
ping to the X chromosome [14]. One of these genes is
DIAPH2 (Diaphanous homolog 2 Drosophila), mapping
to Xq21.33, which affects fertility in female flies by
interfering with follicular cell division. This functional
homology makes DIAPH2 an excellent candidate for the
POI, but its role in the etiology of the disorder is still
unknown [15].
Another candidate for forms of familial and sporadic
POI is FMR1 (Fragile X Mental Retardation 1) gene,
mapping to Xq27.3. It is known that amplification of the
CGG triplet number above the normal range towards
the premutation status of FMR1 acts as a risk factor for
DOR (Diminished ovarian reserve) [16] and POI/POF
[17–19], with a ~ 20 % prevalence of POI in women with
premutated alleles (especially those with 80-99 repeats)
[20]. Furthermore, in a family with an interstitial duplica-
tion encompassing the FMR1 gene, all females carrying
duplicated FMR1 underwent POF condition, suggesting
that FMR1 over-representation is associated to lower ovar-
ian reserve as well as FMR1 premutation.
Here we report molecular characterization and X-
inactivation pattern in a girl with short stature, high
levels of gonadotropins and POI, carrying a de novo bal-
anced X;1 chromosome translocation. The analysis un-
ravelled a mosaic partial inactivation of the translocated
Xq chromosome trait, in addition to the fully skewed
inactivation of the normal X chromosome. Two genes
involved in ovarian deficiency, DIAPH2 and FMR1, were
found dysregulated in peripheral proband's lymphocytes.
Our results support the view that phenotypic anom-
alies of the proband might be caused by a mosaic func-
tional alteration of some translocated genes, caused by
the alteration in spatial nuclear organization, through
a CPE mechanism, as a result of the chromosomal
rearrangement.
Case presentation
The proposita is a 10.5 year-old girl, second born of
non-consanguineous healthy parents. Her elder brother
is referred to be healthy and his stature is 150 cm at
14 years (5th centile for age) (National Center for Health
Statistics in collaboration with the National Center for
Chronic Disease Prevention and Health Promotion
(2000) [21]), with pubertal development of PH3 G3 fol-
lowing Tanner stage. A third pregnancy hesitated in a
spontaneous abortion. Her father is 169 cm whereas her
mother is 150 cm high.
She was born at 39 gestational weeks, after normal
pregnancy, by Caesarian section. Intrauterine growth re-
tardation was detected during last weeks of gestation
and her neonatal weight was 2.400 Kg, with a stature of
48 cm and an occipito-frontal circumference of 33 cm.
In neonatal period, because of heart murmur, she under-
went echocardiographic evaluation that evidenced an ost-
ium secundum interatrial defect, spontaneously closed at
2 years. At 7 years slight hairs covered her back and arms,
and overweigh was noted. Her parents reported slowdown
in growth curve in the last 6 months despite a rapid in-
crease in body weight.
Anthropometric values and clinical findings at 7 years
were: stature 114.6 cm (3-10th centile), weight 25 kg
(75th centile), BMI 19 (90-95th centile). Pubertal devel-
opment was PH1 B1 following Tanner stage; genetic
target was cm 153.5 + 6. At a further observation at
8 years, she presented with healthy condition, short
stature (height cm 116 – below 3rd centile), overweight
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(weight kg 29 – 75th centile, BMI 21.55 – above 95th
centile), hypertrichosis with slightly hairy legs and back,
mild short neck, very mild valgus elbow, and small joint
hyperlaxity, shortening of the fifth metacarpal with syn-
dactyly of 2th and 3th of the toes.
At a first examination, laboratory tests evidenced:
FSH: 12.3 mIU/ml; LH: 0.8 mIU/ml; Estradiol 10.2 pg/
ml. Adrenal and thyroid profiles were within the normal
range for age. Abdominal ultrasound revealed normal
kidney, and pelvic echography showed reduced ovarian
size range for age (right ovary 15 mm × 8 mm × 12 mm;
left 13 mm × 7.4 mm × 10 mm). Because of hairiness in-
crease, a new serum hormonal evaluation was performed
at 7.5 years: laboratory tests showed elevated FSH values
(31.3 mUI/ml) with normal prepuberal values of LH
(0,7 mUI/ml) and Estradiol (13.2 pg/ml); a further pel-
vic ultrasound revealed infantile uterus and confirmed
size reduced ovaries.
Analysis of FMR1 triplet repeat sizes in the proband
by repeat primed PCR [22] revealed sizes in the normal
range (20 to 33 CGG repeats) (data not shown).
During 1-year follow-up period, a POI was suspected
according to high FSH and LH levels and low Estradiol,
inhibin B and AMH levels. Serum FSH and LH values
increased to 179.90 mlU/ml and 40.30 mlU/ml respect-
ively, while Estradiol decreased to 10 pg/ml. Inhibin B
showed a level <20 pg/ml and AMH serum levels were
0.4 ng/ml, well below the normal range.
Bone age of 6 years was assessed by radiological
examination of the left-hand wrist (Tanner e White-
house (TW2) method), despite a chronological age
of 8 years. Stimulation tests for growth hormone
(GH) reserve were performed because of deceleration
of growth curve, increased gap from the stature tar-
get, and retardation of bone age. Testing for GH
revealed a 1.4 ng/ml peak after arginine injection
(0.5 g Arginina/kg in vein infusion in 30 minutes)
and a 4.5 ng/ml peak after clonidine administration
(100 mcg/m2 per os). Replacement therapy with rh-
GH at standard dose for GHD patient was started
(0.23 mg/kg/week). During GH-replacement therapy
follow-up a gain of growth rate (25-50th centile)
with achievement of target height in the first 6 months of
therapy was observed. Any side effect was reported.
Pubertal induction with estroprogestin hormones was
considered in long-term follow-up to prevent the ovar-
ian failure that often occurs in majority cases before pu-
berty and leads to infertility.
Methods
Chromosome analysis
High resolution karyotypes from peripheral blood and
skin fibroblasts of the proband and her parents were
performed according to standard methods.
Fluorescence in situ hybridization (FISH) analysis was
performed using Whole Chromosome Paint (WCP) for
chromosomes X and 1 and LSI XIST probe (MetaSys-
tems, Altlussheim, Germany) on metaphase spreads
and/or interphase nuclei according to manufacturer’s
protocols. Multicolor banding (MCB) was performed
using the multicolor banding DNA Probe Kit (MetaSys-
tems, Altlussheim, Germany) according to manufac-
turer’s protocols [23]. A total of 100 metaphase spreads
and/or 200 nuclei were analyzed.
Late-replicating chromatin was detected as previously
described [24] using mouse monoclonal anti-BrdU (Invi-
trogen Molecular ProbesTM). WCP1 (MetaSystems,
Altlussheim, Germany) was used to paint chromo-
some 1 in the same preparation. Fluorescence assay
of 5-methylcytosine was performed according to the
protocol described by Pfarr et al. [25]. Fluorescent
images were analyzed using a fluorescence micro-
scope (AxioImager.Z1 mot, Zeiss) with ISIS software
imaging system (MetaSystems, Altlussheim, Germany)
for image capturing and processing. Two hundred
nuclei and metaphases were analyzed for each cell
type.
Chromosomal position was evaluated by MCB and
dual color WCP of chromosomes 1 and X. We simpli-
fied the 2D method described by Boyle et al. (2001) [26],
identifying 2 regions in the nucleus, namely an internal
region and an external one.
Array-CGH analysis
Array-CGH of DNA from peripheral blood lymphocytes
and skin fibroblasts of the proband and her parents was
performed by CGX™-HD 4×180K (PerkinElmer Wallac,
Turku, Finland) in accordance with manufacturer’s
guidelines for the whole genome screening. The arrays
were scanned using the InnoScan 710 and analyzed
using Genoglyphix® software (Signature Genomics Spo-
kane, WA), referring to the GRCh37/Hg19 Genome
Assembly. Copy number variations were classified ac-
cording to the Database of Genomic Variants [27], the
DECIPHER Database [28], the UCSC Genome Browser
[29] and the ISCA consortium [30].
qRT-PCR
Total RNA from proband and control whole blood was
extracted using TRIzol reagent (Gibco/BRL Life Tech-
nologies, Inc., Gaithersburg, MD) and was reverse tran-
scribed using the iScript cDNA Synthesis kit (Bio-Rad
Laboratories Inc., Hercules, CA, USA). Real-time PCR
was performed using iQ Supermix SYBR Green 2× on a
Bio-Rad iCycler according to the manufacturer’s proto-
cols. PCR reactions were performed in triplicate. The
primers (MWG Biotech, Ebersberg, Germany) used for
amplification were:
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DIAPH2- For ACCCCAAACAACCCAACAT; Rev
GGTGAAAATCGTTCCCTGTT;
FMR1- For AGAAAAGTACCTGGGGTCACTG; Rev
GCATCCTGATCCTCTCCATAAA.
Primer pairs were designed using the Primer 3 soft-
ware [31] to obtain amplicons ranging from 100 to 150
base pairs. GAPDH housekeeping gene was chosen as
reference gene. Expression values were normalized
versus a pool of RNA from 3 healthy girls matching for
age.
Results
Cytogenetic and molecular analysis
Cytogenetic analysis of the proband, performed at 550
bands on G-banded metaphases from peripheral blood
lymphocytes and skin fibroblasts, revealed a balanced
translocation t(X;1)(q21;q41) (Fig. 1). FISH analysis
using WCP probes for chromosomes X and 1 con-
firmed the conventional banding cytogenetic findings
(data not shown).
Multicolor banding (MCB) for chromosomes X and 1
was performed to further characterize the rearrangement
and the breakpoints. It showed that the region Xq21-
qter was translocated downstream the 1q41 band, giving
rise to the derivative chromosome 1 (der(1)) and that
the 1q42qter trait was translocated to the long arm of
the X-chromosome, giving rise to the derivative X
(der(X)) chromosome (Fig. 2).
Fluorescent BrdU assay, combined with WCP1 probe
FISH, in both lymphocytes and fibroblasts, showed that
the normal X chromosome was always late replicating
and therefore inactivated. Interestingly, we also found
that, in addition to the skewed 100 % inactivation of the
normal X chromosome, part of the Xq21q22 trait, trans-
located to chromosome 1q41, was late replicating and
therefore possibly inactivated in 30 % metaphases both
in lymphocytes and skin fibroblasts (Fig. 3).
FISH analysis using XIST probe (mapping to Xq13.2)
showed signals on both normal X chromosome and
der(X), thus excluding that the Xq inactivation observed
on der(1) is XIST-mediated (Fig. 4).
Fig. 1 Patient G banded karyotype. Karyotype at 550 band resolution shows a reciprocal translocation between 1 and X chromosomes (blue
arrows): t(X;1)(q21;q41)
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To confirm this hypothesis we performed fluorescent
5-methylcytosine (5-Mc) assay that discriminates the
state of heterocromatization in which the chromatin is
densely methylated.
This assay, combined with WCP 1 probe FISH,
showed a hypermethylation, typical of constitutional
heterochromatin, of the Xq21-q22 region of the der(1)
in 30 % metaphases (Fig. 5). This situation might lead
to functional mosaic aneusomy of some translocated
genes and/or gene regulators in this region [32, 33].
We next examined the nuclear positioning of the
normal X and of the late replicating Xq21-q22 trait on
Fig. 2 Multicolor Banding assay. G-Banding images, high resolution multicolor banding (MCB) and ideograms of the derivative 1 and derivative X
chromosomes compared with the normal X chromosome. The region Xq21-qter translocated downstream the region 1q41 is shown
Fig. 3 Late replication assay. Fluorescent BrdU assay, combined with
WCP1 probe FISH, shows that the normal X chromosome was late
replicating (yellow arrow). The late replication also interested the region
Xq21-q22 translocated to der(1) (white arrow). Red arrow points to der(X)
Fig. 4 FISH analysis of XIST. FISH analysis using XIST probe shows the
localization of the XIST gene on normal X chromosome (red arrow)
and on the derivative X chromosome (yellow arrow)
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der(1), performing interphase multicolor banding and
dual DNA-FISH using whole chromosome paint probes
of chromosomes X and 1. Both in skin fibroblasts and in
lymphocytes, normal X was found peripherally in all an-
alyzed nuclei, whereas the translocated Xq21-q22 region
was located peripherally in 30 % of the observed nuclei
(Fig. 6), suggesting that gene expression variation at the
translocated region might be associated to its nuclear
compartmentalization.
Array-CGH analysis
The Oligo-array-CGH analysis of the proband unraveled
only a likely benign partial monosomy of a 159Kb trait
on 10q11.22, representing a copy number variant of un-
certain clinical significance [27, 28, 30]. Array-CGH ana-
lysis excluded any other gain or loss of the proband’s
genome (data not shown).
The complete chromosomal characterization, accord-
ing to ISCN 2013, was as follows: 46,X,t(X;1)(Xpter- >
Xq21::1q42- > 1qter;1pter- > 1q41::Xq21- > Xqter)d-
n.arr[hg19]10q11.22 (46,979,266-47,138,326)x1.
qRT-PCR
Gene expression analysis by qRT-PCR on the RNA from
lymphocytes of the proband showed upregulation of the
DIAPH2 gene, mapping to Xq21.33 (fold change = 2,05),
and of the FMR1 gene, mapping to Xq27.3 (fold change =
1,62), if compared to 3 age matching controls (Fig. 7).
Discussion
Herein we describe a patient with high FSH and LH
levels, pathologic GH stimulation arginine and cloni-
dine tests, short stature, pterygium, ovarian dysgene-
sis, hirsutism and POI. By cytogenetic and molecular
investigations we found a balanced X;1 translocation,
with Xq21-q22 region translocated to 1q41 band.
This region was found to be partially inactivated in
30 % metaphases both in fibroblasts and in lympho-
cytes, in addition to the skewed 100 % inactivation of
the normal X chromosome. We also found that two
genes involved in ovarian deficiency, DIAPH2 and
FMR1, were ovexpressed if compared with normal
controls.
Some possible mechanisms to explain proband ovarian
defect such as microdeletions close to the breakpoints
or XIST-mediated inactivation of the autosomal region
translocated to the der(X) chromosome have been ex-
cluded by array-CGH analysis and FISH analysis using
XIST probe, which also excluded a XIST-mediated inacti-
vation of der(1) segments. MCB analysis also excluded
the involvement of other POI candidate genes such as
FGF16 gene and its syntenic region [7], which are not
included in the translocated trait.
Fig. 5 Fluorescent 5-methylcytosine (5-Mc) assay. 5-Mc antibody,
combined with WCP1 probe FISH, shows that the X region involved
in translocation was heterocromatized (white arrow)
Fig. 6 Nuclear positioning assay. 6A. Interphase Multicolor banding shows the normal X chromosome (yellow arrow) and the Xq21-q22 region on
der(1) (white arrow) located peripherally in the observed nucleus, whereas der(X) is located centrally in the nucleus (blue arrow). 6B. Dual FISH
using whole chromosome painting probes for chromosome 1 (green) and for chromosome X (red) shows the normal X chromosome (yellow
arrow) and the Xq21-q22 region on der(1) (white arrow) located peripherally in the nucleus, whereas der(X) is located centrally in the nucleus
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In agreement with other authors [15, 7] we propose
CPE as alternative possible mechanism to justify the
proband altered phenotype and in general POI pheno-
types in cases of balanced X;autosome translocations
without any evidence of gene dysruption. CPE can be
caused by alterations in local chromatin structure due to
the alterations in nuclear organization that may affect
gene expression [34, 35] leading to variegated pattern of
gene regulation [12, 13].
The study of X-chromosome inactivation in this case,
using fluorescent BrdU assay and fluorescent 5-
methylcytosine assay combined with WCP probe FISH
supported the hypothesis that the alteration in spatial
organization of the derivative chromosomes within the
nucleus might be the cause of the dysregulation of
expression of some X translocated genes, including
DIAPH2 and FMR1. The repositioning of the derivative
chromosome within the nucleus to a more peripheral lo-
cation, as identified by interphase MCB analysis and
dual color whole chromosome painting, suggests that
the variegated inactivation of the X translocated trait
on der(1) could be associated with its nuclear
compartmentalization with derived gene dysregulation,
even though we cannot exclude that gene expression
changes are caused by other factors of genome structure
and function, such as replication timing, which also cor-
relate with nuclear position and repositioning [36].
FMR1 gene maps at Xq27 and is responsible for Fra-
gile X syndrome, a form of X-linked mental retardation.
The female premutation status of FMR1 gene acts as a
risk factor for POI, POF and DOR pathogenesis [16]. A
high variability of FMR1 expression levels has been dem-
onstrated in women carrying an FMR1 premutation,
even though the variance did not directly correlate to
CGGn [37]. Our analysis demonstrated a 60 % overex-
pression of FMR1 gene (Fig. 7) in our patient, in which
molecular studies, previously performed, excluded the
presence of FMR1 premutation status.
As cellular toxicity and increased apoptosis have been
demonstrated in case of FMR1 over-expression, we can-
not exclude that that POI phenotype could be partially
caused by the high expression level of FMR1.
The other gene we found overexpressed in the pro-
band, the DIAPH2 gene [14], affects fertility in female
flies, and has been found disrupted in a family with POI,
though no mutation demonstrated its role in ovarian
function to date. To our knowledge DIAPH2 gene ex-
pression has never been investigated in other families
with POI. This represents the first case in which POI is
associated with an overexpression of DIAPH2. The patient
here reported showed together with POI, other traits of a
Turner like phenotype such as short stature, pterygium
colli and hirsutism. A plausible explanation of all these
clinical features in the proband should be a functional
mosaic double inactivation of genes mapping to the Xq21-
q22 region, as demonstrated by immunofluorescence as-
says, causing a functional Xq partial monosomy.
Conclusions
Our results suggest that POI phenotype of the proband
is caused by a dysregulation of the expression of some
X-linked genes translocated to the chromosome 1,
through either a mechanism of position effect variega-
tion or an alteration in spatial nuclear organization, or
both, as a result of chromosomal rearrangement. Specif-
ically, perturbated genes within region Xq21-qter on
der(1), such as DIAPH2 and FMR1, may be causative
candidate for gonadal dysgenesis and POI in our patient.
Further investigations will be aimed at both assessing
the state of methylation of genes and promoters map-
ping to Xq21-q22 region, and searching for transcrip-
tional regulators affecting the expression of those gene.
This is the second case in which we demonstrate an
inactivation of X traits translocated to autosomes [13],
possibly due to position effect. We suggest that such an
inactivation might affect POI development as well as the
position effect on autosomal genes proposed by other
authors [15].
Epigenetic studies of patients with POI phenotype
might be of considerable relevance to further understand
the etiological mechanisms of POI.
Fig. 7 Gene expression analysis. qRT-PCR in proband versus control
blood shows upregulation of DIAPH2 gene (2,05) and of FMR1 gene
(1,62). Values represent the average determination ± SEM for 2
experiments carried out in triplicate. A pool of RNA from 3 healthy
girls, matching for age was used as calibrator
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Written informed consent was obtained from the patient’s
parents for publication of this Case report and any accom-
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for review by the Editor-in-chief of this journal.
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